February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

product Alfa Laval
Diaphragm valve provides long service life

Alfa Laval’s Unique Diaphragm Valve is designed for aseptic, ultrahygienic, and sterile processes. The valve’s actuator can be fitted with various automation and control units that feature a compact design and facilitate conversion of the control function. The actuator also permits users to adjust the spring pressure to protect the diaphragm against excessive stress. In addition, the manual valves incorporate adjustable overclosure protection. These features help to prolong the life of the diaphragm and increase uptime.

The T- and tank-outlet valves are available in block and forged versions. The forged version weighs approximately 60% less than conventional T- and tank-outlet valve bodies, according to the company. The valves’ light weight makes them quick to heat up during heat sterilization and minimizes the need for piping support of the system. Alfa Laval manufactures the valve with high-quality components, including valve bodies with low delta-ferrite content and diaphragms for continuous-steam applications.


productGE Healthcare
Chromatography media enable high throughput

GE Healthcare’s Capto SP ImpRes cation exchangers and Capto Q ImpRes anion exchangers are designed for final biopharmaceutical purification processes. The products are based on a rigid agarose matrix that enables high flow rates, thus increasing volume throughput and reducing processing times. The rigid matrix also allows personnel to use high bed heights and small column diameters that can reduce the equipment’s footprint. The products’ ability to run at high flow rates and high bed heights gives users flexibility in process design.

The media’s small bead size (~40 µm) helps users achieve high resolution. The SP and Q ligands are intended to ensure predictable performance and robust processing. The ligands also are compatible with common downstream-purification buffers and are identical to those in GE Healthcare’s other ion-exchange media. The high resolution is intended to provide high purity and high yields.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Equipment and Processing Report,
Click here